Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Lysine-specific demethylase 4A–D (KDM4A–D) are a family of JmjC domain-containing enzymes that catalyze the removal of di- and tri-methyl marks from lysine residues on histone H3, specifically at lysines 9 (H3K9) and 36 (H3K36). These demethylases require Fe(II) and alpha-ketoglutarate as cofactors. The KDM4 family plays a central role in epigenetic regulation of chromatin, transcription, DNA replication timing, DNA damage response, and cell cycle control. Overexpression or dysregulation of KDM4A–D, particularly KDM4A, is implicated in various cancers and can lead to altered gene expression, enhanced proliferation, and chromosomal instability. These enzymes are considered promising therapeutic targets, and several small-molecule inhibitors are under development, particularly for oncology indications.
Competitive inhibition of the alpha-ketoglutarate cofactor binding site in the JmjC domain; Inhibition of histone demethylase activity, leading to sustained histone methylation and gene repression/activation
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Lysine-specific demethylase 4A, Lysine-specific demethylase 4B, Lysine-specific demethylase 4C, Lysine-specific demethylase 4D (KDM4A (JMJD2A), KDM4B (JMJD2B), KDM4C (JMJD2C), KDM4D (JMJD2D)).